AI Technology Group Inc. acquires AVM Biotechnology Inc. (2025)

Deal facts

Buyer: AI Technology Group Inc.
Target: AVM Biotechnology Inc.
Deal value: Not disclosed
Announced: 15 December 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

15 Dec 2025CompletedClosed
AI Technology Group Inc. completes acquisition of AVM Biotechnology Inc.
Item 2.01 to amend its Convertible Debentures amounted to $1,587,00, an increase of $462,000, convertible into 634,800 common shares of the Corporation, an increase of 50,000 shares of common stock. Item 1.01 – Entry into a Material Definitive Agreement On December 15, 2025, AI Technology Group Inc. (the “Corporation”) entered into a Share Exchange Agreement as amended hereto with AVM Biotechnolog
Source

OpinionExit Mode editorial

We see a strategic acquisition in the healthcare sector that shifts the balance of power for technology-driven biotech firms. AI Technology Group Inc. has completed its acquisition of AVM Biotechnology Inc. on 15 December 2025. The deal structure is notable because the entire consideration is paid in shares. This is not a cash exit for the founders of AVM Biotechnology. Instead, they remain exposed to the market performance of the combined entity. For the SME founder reading this, the choice to accept shares rather than cash signals a long-term bet on the buyer's ability to integrate and scale the technology.

The cross-border nature of this transaction between two US entities simplifies the regulatory landscape compared to a UK or EU deal, yet the sector remains heavily scrutinised. Healthcare acquisitions always invite attention from competition authorities and sector-specific regulators. While the deal is marked as completed, the integration phase now carries the weight of change-of-control covenants that often trigger in share-based deals. These covenants can restrict the operational autonomy of the acquired team and alter key personnel contracts. The absence of a disclosed value in the announcement is typical for share-swap transactions where the final valuation fluctuates with the stock price until the closing date.

We think the use of a pure share consideration mechanism places the risk of post-close volatility squarely on the seller. In a cash deal, the founder walks away with certainty. Here, the founder's wealth is tied to the buyer's share price movement from the announcement date through to the actual settlement. This structure often serves as a retention tool, binding the target leadership to the new group's success. It also suggests the buyer may be conserving cash for R&D or integration costs, which is a common tactic in the biotech space. The strategic logic appears to be the absorption of specific AI capabilities within a biotech framework rather than a simple financial buyout.

You must review the lock-up period and vesting schedule attached to the shares you received in any similar transaction this week. Do not assume the shares are immediately liquid or that you can sell them without restriction. Check the specific terms regarding the release of your holdings and the conditions under which the buyer can adjust the number of shares issued. Understanding these mechanics is the only way to manage your personal exposure in a share-based exit.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More strategic acquisition deals More from AI Technology Group Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history